Expasy logo

UniProtKB/Swiss-Prot variant pages

UniProtKB/Swiss-Prot Q8IY63: Variant p.Arg157Cys

Angiomotin-like protein 1
Gene: AMOTL1
Feedback?
Variant information Variant position: help 157 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant: help LP/P [Disclaimer] The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance
Residue change: help From Arginine (R) to Cysteine (C) at position 157 (R157C, p.Arg157Cys). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties: help Change from large size and basic (R) to medium size and polar (C) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score: help -3 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page
Variant description: help In CFCHS; likely pathogenic. Any additional useful information about the variant.


Sequence information Variant position: help 157 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: help 956 The length of the canonical sequence.
Location on the sequence: help NFSSTENLTQEDPQMVYQSA R QEPQGQEHQVDNTVMEKQVR The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: help The multiple alignment of the region surrounding the variant against various orthologous sequences. 
Human                         NFSSTENLTQEDPQMVYQSARQEPQGQEHQVDNTVMEKQVR

Mouse                         NFSSTETLTQEDPQMVYQSARQEPQGQEHQGDNTVMEKQVR

Bovine                        NFSSTENLAQEDPQMVYQSARQEPQGQEHQVDNTVMEKQVR
Sequence annotation in neighborhood: help The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.
TypePositionsDescription
Chain 1 – 956 Angiomotin-like protein 1



Literature citations
Using human sequencing to guide craniofacial research.
Liegel R.P.; Finnerty E.; Blizzard L.; DiStasio A.; Hufnagel R.B.; Saal H.M.; Sund K.L.; Prows C.A.; Stottmann R.W.;
Genesis 57:e23259-e23259(2019)
Cited for: VARIANT CFCHS CYS-157; VARIANT CYS-238;
A mutational hotspot in AMOTL1 defines a new syndrome of orofacial clefting, cardiac anomalies, and tall stature.
Strong A.; Rao S.; von Hardenberg S.; Li D.; Cox L.L.; Lee P.C.; Zhang L.Q.; Awotoye W.; Diamond T.; Gold J.; Gooch C.; Gowans L.J.J.; Hakonarson H.; Hing A.; Loomes K.; Martin N.; Marazita M.L.; Mononen T.; Piccoli D.; Pfundt R.; Raskin S.; Scherer S.W.; Sobriera N.; Vaccaro C.; Wang X.; Watson D.; Weksberg R.; Bhoj E.; Murray J.C.; Lidral A.C.; Butali A.; Buckley M.F.; Roscioli T.; Koolen D.A.; Seaver L.H.; Prows C.A.; Stottmann R.W.; Cox T.C.;
Am. J. Med. Genet. A 191:1227-1239(2023)
Cited for: VARIANTS CFCHS CYS-157; HIS-157; LEU-160; ARG-161; ALA-368 AND LYS-579; VARIANT LYS-507;
Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.